Publications by authors named "Philip J Rybczynski"

12Publications

Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.

Bioorg Med Chem Lett 2007 Dec 17;17(24):6773-8. Epub 2007 Oct 17.

Drug Discovery, Johnson & Johnson, East Coast RED, Spring House, PA 19477-0776, USA.

View Article and Find Full Text PDF
December 2007

Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.

Bioorg Med Chem Lett 2006 Mar 27;16(6):1696-701. Epub 2005 Dec 27.

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
March 2006

Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.

Bioorg Med Chem Lett 2005 Dec 28;15(23):5202-6. Epub 2005 Sep 28.

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
December 2005

Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors.

Bioorg Med Chem Lett 2005 Nov;15(21):4790-3

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
November 2005

Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors.

Bioorg Med Chem Lett 2004 Oct;14(20):5121-5

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
October 2004

Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists.

Bioorg Med Chem Lett 2004 Jun;14(12):3143-6

Endocrine Therapeutics and Metabolic Disorders, Johnson and Johnson Pharmaceutical Research and Development, LLC, 1000 Route 202, Bldg: PCC, Room: PC110, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
June 2004

2,5-disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists.

Bioorg Med Chem Lett 2003 Nov;13(22):4031-4

Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development L.L.C., 1000 Route 202, Raritan, NJ 08869-0602, USA.

View Article and Find Full Text PDF
November 2003

Hepatic biotransformation of the new calcium-mimetic agent, RWJ-68025, in the rat and in man--API-MS/MS identification of metabolites.

J Pharm Pharmacol 2003 May;55(5):631-7

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Spring House, PA, USA.

View Article and Find Full Text PDF
May 2003

Benzoxazinones as PPARgamma agonists. part 1: SAR of three aromatic regions.

Bioorg Med Chem Lett 2003 Jul;13(14):2359-62

Johnson and Johnson Pharmaceutical Research and Development, LLC, 08869, Raritan, NJ, USA.

View Article and Find Full Text PDF
July 2003

Treatment of non-insulin-dependent diabetes mellitus.

Expert Opin Investig Drugs 2003 Apr;12(4):623-33

Room PC110, Bldg: PCC, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
April 2003